

Product Information Sheet for NR-9597

Cowpox Virus, Brighton Red Recombinant Expressing Enhanced Green Fluorescent Protein

Catalog No. NR-9597

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Arthur Goff, Ph.D., Viral Therapeutics Branch, Virology Division, United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Maryland

Product Description:

Virus Classification: Poxviridae, Orthopoxvirus

Agent: Cowpox Virus

Strain: Brighton Red recombinant expressing enhanced green fluorescent protein (GFP)

<u>Preparation</u>: A recombinant cowpox virus was constructed that expresses enhanced GFP under the control of the vaccinia virus p7.5 early/late promoter between the counterparts of the vaccinia virus Copenhagen genes J4R and J5L.1

Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from infected African green monkey MA-104 Clone 1 cells (BEI Resources NR-595).

Packaging/Storage:

The recombinant cowpox virus preparation was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -70°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

<u>Host</u>: MA-104 Clone 1 cells (ATCC[®] CRL-2378.1[™] or BEI Resources NR-595)

<u>Growth Medium</u>: Minimum Essential Medium with Earle's salts and non-essential amino acids supplemented with 2% fetal bovine serum, or equivalent

Infection: Cells should 80 to 90% confluent (not 100% confluent)

Incubation: 3 to 7 days at 37°C and 5% CO₂
Cytopathic Effect: Cell rounding and cell lysis

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Cowpox Virus, Brighton Red Recombinant Expressing Enhanced Green Fluorescent Protein, NR-9597."

Biosafety Level: 2

Appropriate safety procedures should always be used with

this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm. This publication recommends that all persons working in or entering laboratory or animal care areas where activities with cowpox virus are being conducted should have documented evidence of satisfactory vaccination within the preceding ten years.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

 Goff, A., et al. "In vivo Imaging of Cidofovir Treatment of Cowpox Virus Infection." <u>Virus Res.</u> 128 (2007): 88-98. PubMed: 17524511.

ATCC® is a trademark of the American Type Culture Collection.



Biodefense and Emerging Infections Research Resources Repository

800-359-7370

Fax: 703-365-2898

E-mail: contact@beiresources.org